Policy and regulation

NICE approves stomach tumour treatment

2009-09-23T11:10:00

Sunitinib has been recommended by NICE for gastro-intestinal stromal tumours (Gists) after a pricing deal with maker Pfizer.

Source: MAXPPP

Sunitinib has been recommended by NICE for gastro-intestinal stromal tumours after a pricing deal with maker Pfizer.

You need to be signed in to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Subscribe

to HSJ

Sign into your account here